One of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use.
Recognizing this fact, the Golden Helix Foundation organizes in London the 1st U-PGx Personalized Medicine Public Day. The meeting will be organized in the Royal Society in the afternoon of December 6th, 2017 (18:00 – 21:30 p.m.) and is part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The theme of the event is “Is Personalised Medicine available for every citizen“.
This event is meant for the general public, patient organisations, regulators, insurers and policy makers.
Registration is FREE-OF-CHARGE. During the break, drinks and food will be served for free.
Organized by: |
Funded by: |
Under the auspices of: |
 |
IntroductionAbout U-PGXSpeakersScientific ProgramGalleryOne of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use.
Recognizing this fact, the Golden Helix Foundation organizes in London the 1st U-PGx Personalized Medicine Public Day. The meeting will be organized in the Royal Society in the afternoon of December 6th, 2017 (18:00 – 21:30 p.m.) and is part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The theme of the event is “Is Personalised Medicine available for every citizen“.
This event is meant for the general public, patient organisations, regulators, insurers and policy makers.
Registration is FREE-OF-CHARGE. During the break, drinks and food will be served for free.
| Organized by: | Funded by: |
| Under the auspices of: | |
Ubiquitous Pharmacogenomics (U-PGx)
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Invited Speakers
Keynote Speaker and moderator:
Sir Munir Pirmohamed (University of Liverpool, UK)
Plenary speakers:
Darrol Baker (The Golden Helix Foundation, London, UK)
David Haerry (European Aids Treatment Group, Brussels, Belgium)
Anneke Seller (NHS, London, UK)
Jayne Spink (Genetic Alliance UK, London, UK)
Scientific Program
18:00 – 18:30 REGISTRATION
18:30 – 18:40 Darrol J. Baker
Director; the Golden Helix Foundation, London, UK
Welcome address
18:40 – 19:10 KEYNOTE LECTURE – Sir Munir Pirmohamed
David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics; Associate Executive Pro-Vice Chancellor for Clinical Research; Director, MRC Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine, Liverpool, UK
Pharmacogenomics: Relevance for patient care
19:10 – 19:30 Anneke Seller
Director; Genomics Educational Program, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
TBA
19:30 – 19:50 Jayne Spink
Chief Executive; Genetic Alliance UK, London, UK
Personalized Medicine and Me: Rare and genetic conditions – a patient view
19:50 – 20:10 David Haerry
Director; European AIDS Teatment Group (EATG), Brussels, Belgium
Patients and Drug development: Why collaboration matters
20:10 – 20:30 General Discussion (moderated by Sir Munir Pirmohamed)
20:30 – 20:40 Darrol J. Baker
Director; the Golden Helix Foundation, London, UK
Concluding remarks
20:40 – 21:30 RECEPTION
Gallery
